Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study

Abstract

We aimed to assess the safety and efficacy of lobeglitazone in patients with type 2 diabetes over 52 weeks through 28-week extension study. Clinical benefits in terms of glycemic and lipid control were maintained for 52 weeks. Lobeglitazone showed a favorable balance of efficacy and safety during the extension study.

References

Page 1

	Year	Citations
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy Steven E. Kahn, Steven M. Haffner, Mark Heise, New England Journal of Medicine	2006	2.9K
Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. S Aronoff, Sidney Rosenblatt, Susan S. Braithwaite, Diabetes Care	2000	628
One-Year Glycemic Control With a Sulfonylurea Plus Pioglitazone Versus a Sulfonylurea Plus Metformin in Patients With Type 2 Diabetes M Hanefeld, Paolo Brunetti, Guntram Schernthaner, Diabetes Care	2004	230
Use of Antidiabetic Drugs in the U.S., 2003–2012 Christian Hampp, Vicky Borders‐Hemphill, David Moeny, Diabetes Care	2014	212
A long‐term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double‐blind, parallel‐group comparison trial B Charbonnel, David R. Matthews, Guntram Schernthaner, Diabetic Medicine	2005	143
Efficacy and Safety of Lobeglitazone Monotherapy in Patients with Type 2 Diabetes Mellitus over 24-Weeks: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Trial Sin Gon Kim, Doo Man Kim, Jeong‐Taek Woo, PLoS ONE	2014	79
Lobeglitazone and pioglitazone as add‐ons to metformin for patients with type 2 diabetes: a 24‐week, multicentre, randomized, double‐blind, parallel‐group, active‐controlled, phase <scp>III</scp> clinical trial with a 28‐week extension Sang‐Man Jin, C.‐Y. Park, Y. M. Cho, Diabetes Obesity and Metabolism Metabolic SyndromeDiabetes ManagementWeek 24Cardiovascular DiseaseInsulin Management	2015	49

Page 1